[Clinical usefulness of fetal fibronectin (fFN) expression in cervico-vaginal secretions (CVS)].
García Alonso
L A
LA
Departamento de Medicina Perinatal, Hospital de Gineco-obstetricia Luis Castelazo Ayala, IMSS.
Jiménez
S G
SG
Ayala Méndez
J A
JA
Izquierdo Puente
J C
JC
Barahona
B E D C
BE
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001724:Birth Weight; D002584:Cervix Uteri / Q000378:metabolism*; D005260:Female; D005313:Fetal Death / Q000175:diagnosis / Q000209:etiology; D005353:Fibronectins; D005865:Gestational Age; D006023:Glycoproteins / Q000032:analysis*; D006801:Humans; D007231:Infant, Newborn; D007752:Obstetric Labor, Premature / Q000175:diagnosis* / Q000517:prevention & control; D011237:Predictive Value of Tests; D011247:Pregnancy; D012680:Sensitivity and Specificity; D015149:Tocolytic Agents / Q000627:therapeutic use; D014621:Vagina / Q000378:metabolism*
D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; C403421:FFN protein, human; D005353:Fibronectins; D006023:Glycoproteins; D015149:Tocolytic Agents